Here are five observations:
1. The growing popularity of biologics among surgeons and the minimally invasiveness of the procedure will boost the market.
2. The costliness of the biologics process will prove detrimental to market growth.
3. North America leads the space, with Europe coming in second.
4. The Asia-Pacific market will likely significantly grow, owing to an increasing population and improving medical technologies, among other factors.
5. Dominant market players include Alphatec Spine, DePuy Spine, Medtronic, Stryker, Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.
More articles on biologics:
3D-printed PEEK vs. PEKK for spine surgery: 5 takeaways from new study
SeaSpine earns FDA clearance for new OsteoBallast product: 5 things to know
MD Stem Cells reports positive initial results for SCI study: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
